SLU-PP-332
A small-molecule ERRα/γ agonist studied as an exercise mimetic, shown to increase oxidative muscle fiber composition and endurance capacity in preclinical models.
Also referenced as: SLU PP 332
Also appears in: Performance
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when SLU-PP-332 crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Metabolic. Also surfaces under Performance for browsing and discovery.
SLU PP 332
No FDA label signal · 0 trials · 10 PubMed results
Current evidence for SLU-PP-332 is limited to laboratory or animal studies — there are no name-matched human trials with reported results. Any claims about effects in people are not yet backed by clinical data.
SLU-PP-332 has no clinical trials that name it and 10 PubMed-indexed publications and is not FDA-approved. Current evidence is preclinical or mechanistic.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What is SLU-PP-332?
SLU-PP-332 is a synthetic small molecule — not a peptide — that acts as an agonist of estrogen-related receptors alpha and gamma (ERRα/γ). These nuclear receptors regulate genes involved in mitochondrial biogenesis, fatty acid oxidation, and oxidative metabolism. Like 5-Amino-1MQ, SLU-PP-332 is categorized alongside peptides by research vendors despite being a different compound class.
How it works
- ERR activation — ERRα and ERRγ are orphan nuclear receptors that regulate the same metabolic gene programs normally activated by endurance exercise (Rangwala et al., Journal of Biological Chemistry, 2010)
- Muscle fiber switching — in mice, SLU-PP-332 increased the proportion of oxidative (type I and IIa) muscle fibers, which are associated with fatigue resistance (Kim et al., bioRxiv, 2023; later published)
- Endurance improvement — treated mice showed significantly increased treadmill running time and distance compared to controls without exercise training (Kim et al., bioRxiv, 2023)
- Fat metabolism — ERR activation upregulates genes involved in fatty acid beta-oxidation, shifting fuel utilization toward lipids
Research status
SLU-PP-332 is very early-stage with limited published data:
- Willy et al. (2004) identified ERRα/γ as regulators of oxidative metabolism gene programs (Molecular and Cellular Biology, 24(18):7931–7941)
- Rangwala et al. (2010) developed early ERR agonists and demonstrated metabolic effects (Journal of Biological Chemistry, 285(47):36824–36831)
- Kim et al. (2023) published the key exercise-mimetic study showing muscle fiber switching and endurance gains in mice without exercise (bioRxiv, later presented at ACS Spring 2024)
No human clinical trials or formal toxicology studies have been published.
Key considerations
- Not a peptide — it is an inverse agonist/agonist-class small molecule sold alongside peptides by research vendors
- The “exercise in a pill” framing is based on a single rodent study; human translation is speculative
- The compound was developed at Saint Louis University (SLU) for receptor pharmacology research, not as a therapeutic candidate
- Available from research vendors as capsules or powder, but purity standards vary since it is not a widely manufactured pharmaceutical intermediate